A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

Completed · Phase 1/Phase 2

Conditions studied: Glioblastoma

In brief

This is an open label, multi-center, phase 1 safety run-in and phase 2 study of BBI608 in combination with temozolomide in patients with recurrent or progressive glioblastoma who have not received prior bevacizumab therapy.

Key facts

Study ID

NCT02315534

Run by

Sumitomo Pharma America, Inc.

People needed

34

Starts

2015-03-01

Expected to finish

2019-06-24

Last updated by the study team

2023-11-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Laura and Isaac Perlmutter Cancer Center — New York, New York, United States
• University of Calgary — Calgary, Alberta, Canada
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.